QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
Most-Downgraded StocksMost-Downgraded
NASDAQ:APLS

Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

$38.94
+1.80 (+4.85%)
(As of 10/3/2023 ET)
Compare
Today's Range
$36.32
▼
$39.64
50-Day Range
$23.65
▼
$48.53
52-Week Range
$19.83
▼
$94.75
Volume
2.14 million shs
Average Volume
2.80 million shs
Market Capitalization
$4.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.13
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
69.9% Upside
$66.13 Price Target
Short Interest
Bearish
11.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.63mentions of Apellis Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$10.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.89) to ($2.77) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

138th out of 976 stocks

Pharmaceutical Preparations Industry

43rd out of 447 stocks

See Top Rated MarketRank™ Stocks Here

APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Price History

APLS Stock News Headlines

October 2, 2023 | markets.businessinsider.com
Apellis Pharmaceuticals Announces FDA Approval Of EMPAVELI Injector - Quick Facts
October 2, 2023 | finance.yahoo.com
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
October 3, 2023 | Stansberry Research (Ad)
Investing Legend Warns: NVIDIA is a "Delusion"
Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.
October 2, 2023 | americanbankingnews.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Large Growth in Short Interest
September 29, 2023 | tmcnet.com
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
September 29, 2023 | markets.businessinsider.com
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
September 28, 2023 | barrons.com
MONDAY INVESTOR DEADLINE: Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 28, 2023 | americanbankingnews.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from Analysts
October 3, 2023 | Oxford Club (Ad)
The Ultimate Passive Income Play
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.
September 27, 2023 | msn.com
Apellis Pharmaceuticals sinks amid new short report
September 27, 2023 | americanbankingnews.com
Apellis Pharmaceuticals (NASDAQ:APLS) Receives Buy Rating from HC Wainwright
September 25, 2023 | stockhouse.com
OCTOBER 2 DEADLINE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 25, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and DENTSPLY SIRONA (XRAY)
September 25, 2023 | finance.yahoo.com
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
September 24, 2023 | prnewswire.com
APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
September 24, 2023 | americanbankingnews.com
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%
September 22, 2023 | benzinga.com
Apellis Pharmaceuticals Unusual Options Activity For September 22
September 21, 2023 | markets.businessinsider.com
Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS)
September 20, 2023 | markets.businessinsider.com
Apellis Pharmaceuticals: Strong Competitive Positioning and Safety Confidence Reinforce Buy Rating
September 19, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (BSX), Apellis Pharmaceuticals (APLS) and Healthequity (HQY)
September 19, 2023 | barrons.com
S&P 500 Futures Climb in Premarket Trading; Apellis Pharmaceuticals, Liberty Media SiriusXM A Lead
September 19, 2023 | proactiveinvestors.com
Apellis Pharmaceuticals gets schadenfreude lift as rival trial fails
September 19, 2023 | proactiveinvestors.com
Apellis Pharmaceuticals sees schadenfreude stock boost as rival trial fails
September 19, 2023 | msn.com
Apellis spikes as Astellas posts long-term data for rival product
September 16, 2023 | markets.businessinsider.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
September 15, 2023 | msn.com
Wells Fargo ups Apellis to overweight, stock climbs 8%
September 15, 2023 | msn.com
Wells Fargo Upgrades Apellis Pharmaceuticals (APLS)
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
7/31/2023
Today
10/03/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
CUSIP
N/A
CIK
1492422
Web
www.apellis.com
Phone
(617) 977-5700
Fax
N/A
Employees
767
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$66.13
High Stock Price Forecast
$141.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+70.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-652,170,000.00
Net Margins
-356.02%
Pretax Margin
-356.37%
Return on Equity
-212.82%
Return on Assets
-74.50%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
5.11
Quick Ratio
4.52

Sales & Book Value

Annual Sales
$75.42 million
Price / Sales
60.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.54 per share
Price / Book
25.16

Miscellaneous

Outstanding Shares
117,740,000
Free Float
108,907,000
Market Cap
$4.56 billion
Optionable
Not Optionable
Beta
1.10

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Cedric Francois M.D. (Age 51)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $1.2M
  • Dr. Pascal Deschatelets Ph.D. (Age 53)
    Co-Founder & Chief Scientific Officer
    Comp: $688.05k
  • Mr. Alec Machiels J.D.Mr. Alec Machiels J.D. (Age 50)
    MBA, Co-Founder & Director
    Comp: $72.5k
  • Mr. Timothy E. SullivanMr. Timothy E. Sullivan (Age 52)
    CFO & Treasurer
    Comp: $716.41k
  • Mr. David O. Watson Esq.Mr. David O. Watson Esq. (Age 50)
    J.D., Gen. Counsel
    Comp: $675.35k
  • Mr. Adam J. TownsendMr. Adam J. Townsend (Age 46)
    Chief Commercial Officer
    Comp: $701.61k
  • Ms. Nur NicholsonMs. Nur Nicholson (Age 54)
    Chief Technical Operations Officer
  • Mr. James G. Chopas CPA (Age 57)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Meredith Kaya
    Sr. VP, Investor Relations & Strategic Fin.
  • Ms. Karen LewisMs. Karen Lewis (Age 51)
    Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2023?

15 Wall Street research analysts have issued twelve-month price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $29.00 to $141.00. On average, they expect the company's stock price to reach $66.13 in the next year. This suggests a possible upside of 70.7% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of 2023. Since then, APLS stock has decreased by 25.1% and is now trading at $38.75.
View the best growth stocks for 2023 here.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,610,000 shares, an increase of 10.6% from the August 31st total of 12,310,000 shares. Based on an average daily volume of 4,730,000 shares, the short-interest ratio is presently 2.9 days.
View Apellis Pharmaceuticals' Short Interest.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our APLS earnings forecast.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its earnings results on Monday, July, 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.33. The business had revenue of $95 million for the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 212.82% and a negative net margin of 356.02%. The business's quarterly revenue was up 482.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.46) earnings per share.

What ETFs hold Apellis Pharmaceuticals' stock?

ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI).

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $38.75.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $4.56 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 767 workers across the globe.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -